Indefinite Delivery Contract 36E79726D0005

Golden State Medical Supply, Inc. has been awarded a single-award Indefinite Delivery Contract by the Department of Veterans Affairs National Acquisition Center for the supply of Ambrisentan Tablets. The contract, effective April 1, 2026 through March 31, 2027, carries a ceiling value of $6.9 million and includes four one-year option periods, providing potential contract continuity through March 31, 2030. This civilian agency procurement is unrestricted and available to all responsible offerors, with no set-aside designation applied. The annual requirements total 3,439 bottles per year, comprising 966 bottles of 5-milligram strength and 2,473 bottles of 10-milligram strength. Ambrisentan is an endothelin receptor antagonist indicated for pulmonary arterial hypertension management, and the contracted supply will serve multiple federal healthcare systems including the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center through established Pharmaceutical Prime Vendor Programs.

The procurement was structured as an unrestricted commercial item acquisition under NAICS code 325412 (pharmaceutical preparation manufacturing) and Product Service Category 6505 (Drugs and Biologicals). Products supplied must bear Golden State Medical Supply's unique National Drug Code identifier as the sole manufacturer label, ensuring product authenticity and traceability within federal pharmaceutical distribution networks. This contract represents Golden State Medical Supply's continued role as a critical pharmaceutical supplier to federal healthcare agencies and aligns with the company's extensive portfolio of single-award Indefinite Delivery Contracts covering multiple medication categories with similar base period plus four-year option structures.